Premium
Vildagliptin: alternative add‐on therapy for oral glycaemic control
Author(s) -
Chaplin Steve,
Campbell Ian
Publication year - 2008
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.294
Subject(s) - vildagliptin , medicine , metformin , adverse effect , diabetes mellitus , type 2 diabetes , intensive care medicine , dipeptidyl peptidase 4 , pharmacology , endocrinology
Vildagliptin, an oral DPP‐4 inhibitor, is licensed as an add‐on therapy when adequate glycaemic control has not been achieved with metformin, a sulphonylurea or a glitazone. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Professor Ian Campbell comments on its place in type 2 diabetes therapy. Copyright © 2008 Wiley Interface Ltd